Teva Pharmaceutical Industries annual debt-to-equity ratio
2008
2009
2010
2011
2012
2013
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Teva Pharmaceutical Industries Debt-to-Equity Ratio Growth & History (TEVA)
Teva Pharmaceutical Industries's debt-to-equity ratio was 0.28 for fiscal 2025.
View full Teva Pharmaceutical Industries company overviewTeva Pharmaceutical Industries annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.28 | −0.12 | −30.27% |
| 2024 | 2024-12-31 | 0.41 | 0.12 | +44.05% |
| 2023 | 2023-12-31 | 0.28 | −0.05 | −14.29% |
| 2022 | 2022-12-31 | 0.33 | 0.14 | +71.49% |
| 2021 | 2021-12-31 | 0.19 | −0.19 | −49.33% |
| 2020 | 2020-12-31 | 0.38 | 0.17 | +81.11% |
| 2019 | 2019-12-31 | 0.21 | 0.06 | +39.03% |
| 2018 | 2018-12-31 | 0.15 | −1.51 | −90.93% |
| 2017 | 2017-12-31 | 1.66 | 0.68 | +70.15% |
| 2016 | 2016-12-31 | 0.98 | — | — |
| 2013 | 2013-12-31 | 0.50 | −0.12 | −20.08% |
| 2012 | 2012-12-31 | 0.62 | 0.11 | +21.00% |
| 2011 | 2011-12-31 | 0.51 | 0.45 | +679.70% |
| 2010 | 2010-12-31 | 0.07 | −0.01 | −14.26% |
| 2009 | 2009-12-31 | 0.08 | −0.21 | −73.40% |
| 2008 | 2008-12-31 | 0.29 | — | — |
Teva Pharmaceutical Industries quarterly debt-to-equity ratio
Q4.08
Q1.09
Q2.09
Q3.09
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
As of Dec 31, 2014
As of Mar 31, 2015
As of Jun 30, 2015
As of Sep 30, 2015
As of Dec 31, 2015
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.62 | 0.51 | +454.06% |
| Q1 2026 | 2026-03-31 | 0.35 | 0.24 | +210.44% |
| Q4 2025 | 2025-12-31 | 0.28 | −0.12 | −30.27% |
| Q3 2025 | 2025-09-30 | 0.04 | −0.43 | −91.07% |
| Q2 2025 | 2025-06-30 | 0.11 | −0.26 | −70.19% |
| Q1 2025 | 2025-03-31 | 0.11 | −0.35 | −75.43% |
| Q4 2024 | 2024-12-31 | 0.41 | 0.12 | +44.05% |
| Q3 2024 | 2024-09-30 | 0.47 | 0.21 | +82.17% |
| Q2 2024 | 2024-06-30 | 0.37 | 0.04 | +13.62% |
| Q1 2024 | 2024-03-31 | 0.46 | 0.29 | +164.78% |
| Q4 2023 | 2023-12-31 | 0.28 | −0.05 | −14.29% |
| Q3 2023 | 2023-09-30 | 0.26 | −0.10 | −26.95% |
| Q2 2023 | 2023-06-30 | 0.33 | 0.10 | +42.13% |
| Q1 2023 | 2023-03-31 | 0.17 | −0.09 | −34.16% |
| Q4 2022 | 2022-12-31 | 0.33 | 0.14 | +71.49% |
| Q3 2022 | 2022-09-30 | 0.36 | 0.06 | +18.97% |
| Q2 2022 | 2022-06-30 | 0.23 | −0.15 | −39.92% |
| Q1 2022 | 2022-03-31 | 0.26 | −0.05 | −15.76% |
| Q4 2021 | 2021-12-31 | 0.19 | −0.19 | −49.33% |
| Q3 2021 | 2021-09-30 | 0.30 | 0.03 | +11.42% |
| Q2 2021 | 2021-06-30 | 0.38 | 0.24 | +158.46% |
| Q1 2021 | 2021-03-31 | 0.31 | 0.16 | +108.04% |
| Q4 2020 | 2020-12-31 | 0.38 | 0.17 | +81.11% |
| Q3 2020 | 2020-09-30 | 0.27 | 0.00 | +1.01% |
| Q2 2020 | 2020-06-30 | 0.15 | −0.09 | −37.10% |
| Q1 2020 | 2020-03-31 | 0.15 | −0.08 | −33.75% |
| Q4 2019 | 2019-12-31 | 0.21 | 0.06 | +39.03% |
| Q3 2019 | 2019-09-30 | 0.27 | 0.12 | +76.48% |
| Q2 2019 | 2019-06-30 | 0.24 | 0.17 | +233.93% |
| Q1 2019 | 2019-03-31 | 0.23 | 0.16 | +225.61% |
| Q4 2018 | 2018-12-31 | 0.15 | −1.51 | −90.93% |
| Q3 2018 | 2018-09-30 | 0.15 | −0.96 | −86.48% |
| Q2 2018 | 2018-06-30 | 0.07 | −1.14 | −94.15% |
| Q1 2018 | 2018-03-31 | 0.07 | −0.90 | −92.76% |
| Q4 2017 | 2017-12-31 | 1.66 | 0.68 | +70.15% |
| Q3 2017 | 2017-09-30 | 1.12 | 0.17 | +18.07% |
| Q2 2017 | 2017-06-30 | 1.21 | 0.95 | +354.62% |
| Q1 2017 | 2017-03-31 | 0.97 | 0.68 | +239.83% |
| Q4 2016 | 2016-12-31 | 0.98 | 0.69 | +244.56% |
| Q3 2016 | 2016-09-30 | 0.94 | 0.85 | +899.85% |
| Q2 2016 | 2016-06-30 | 0.27 | 0.14 | +103.19% |
| Q1 2016 | 2016-03-31 | 0.28 | 0.21 | +295.43% |
| As of Dec 31, 2015 | 2015-12-31 | 0.28 | −0.09 | −23.31% |
| As of Sep 30, 2015 | 2015-09-30 | 0.09 | 0.02 | +21.86% |
| As of Jun 30, 2015 | 2015-06-30 | 0.13 | 0.04 | +50.77% |
| As of Mar 31, 2015 | 2015-03-31 | 0.07 | 0.00 | +6.30% |
| As of Dec 31, 2014 | 2014-12-31 | 0.37 | −0.13 | −25.59% |
| Q3 2014 | 2014-09-30 | 0.08 | −0.04 | −31.81% |
| Q2 2014 | 2014-06-30 | 0.09 | −0.03 | −26.13% |
| Q1 2014 | 2014-03-31 | 0.07 | −0.05 | −43.57% |
| Q4 2013 | 2013-12-31 | 0.50 | −0.12 | −20.08% |
| Q3 2013 | 2013-09-30 | 0.11 | 0.09 | +356.60% |
| Q2 2013 | 2013-06-30 | 0.12 | 0.08 | +201.41% |
| Q1 2013 | 2013-03-31 | 0.12 | −0.05 | −28.00% |
| Q4 2012 | 2012-12-31 | 0.62 | 0.11 | +21.00% |
| Q3 2012 | 2012-09-30 | 0.02 | −0.12 | −82.66% |
| Q2 2012 | 2012-06-30 | 0.04 | −0.04 | −51.97% |
| Q1 2012 | 2012-03-31 | 0.17 | 0.11 | +186.18% |
| Q4 2011 | 2011-12-31 | 0.51 | 0.45 | +679.70% |
| Q3 2011 | 2011-09-30 | 0.14 | 0.09 | +185.45% |
| Q2 2011 | 2011-06-30 | 0.08 | −0.02 | −20.06% |
| Q1 2011 | 2011-03-31 | 0.06 | −0.04 | −43.49% |
| Q4 2010 | 2010-12-31 | 0.07 | −0.01 | −14.26% |
| Q3 2010 | 2010-09-30 | 0.05 | −0.07 | −58.01% |
| Q2 2010 | 2010-06-30 | 0.10 | −0.06 | −37.24% |
| Q1 2010 | 2010-03-31 | 0.10 | −0.18 | −63.77% |
| Q4 2009 | 2009-12-31 | 0.08 | −0.21 | −73.40% |
| Q3 2009 | 2009-09-30 | 0.12 | — | — |
| Q2 2009 | 2009-06-30 | 0.16 | — | — |
| Q1 2009 | 2009-03-31 | 0.28 | — | — |
| Q4 2008 | 2008-12-31 | 0.29 | — | — |
Teva Pharmaceutical Industries debt-to-equity ratio trends
Over the last five fiscal years, Teva Pharmaceutical Industries's debt-to-equity ratio decreased from 0.38 to 0.28, a change of −0.10. The latest reported quarter, Q2 2026, shows 0.62.
About the metric
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
Calculation and source
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Teva Pharmaceutical Industries source filings ↗